Cargando…
Management of osteoporosis
Osteoporosis or osteopenia occurs in about 44 million Americans, resulting in 1.5 million fragility fractures per year. The consequences of these fractures include pain, disability, depression, loss of independence, and increased mortality. The burden to the healthcare system, in terms of cost and r...
Autor principal: | Lewiecki, E Michael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC493281/ https://www.ncbi.nlm.nih.gov/pubmed/15253771 http://dx.doi.org/10.1186/1476-7961-2-9 |
Ejemplares similares
-
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008) -
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2009) -
Operationalizing Treat-to-Target for Osteoporosis
por: Lewiecki, E. Michael
Publicado: (2021) -
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011) -
Anabolic therapy for osteoporosis: update on efficacy and safety
por: Bandeira, Leonardo, et al.
Publicado: (2022)